Cognitive Deficits in Schizophrenia Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-288 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia.
This is a Phase 2 study designed to evaluate the efficacy and safety of ABT-288 in
approximately 210 adults with schizophrenia. Subjects will be randomized to one of three
treatment groups (ABT-288 Dose 1, ABT-288 Dose 2 or placebo) for a 12-week Treatment Period.
The purpose of this research study is to find out whether ABT-288 compared to placebo can
improve cognition and what side effects ABT 288 may cause. Cognition is the way a person
thinks, and it includes abilities like paying attention, focusing, remembering things, and
solving problems. Acronyms listed in the Outcomes and/or Eligibility sections for this study
are defined below:
- MCCB: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS)
Consensus Cognitive Battery
- UPSA-2: University of California at San Diego (UCSD) Performance-Based Skills
Assessment-2
- CANTAB: Cambridge Neuropsychological Test Automated Battery
- PANSS: Positive and Negative Syndrome Scale
- NSA-16: Negative Symptom Assessment-16
- CGI-S: Clinical Global Impression - Severity
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01095562 -
Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia
|
Phase 2 |